Mikele Bicolli
Dec 28, 2023

Pharmaceutical Patents Set to Expire in 2024: Implications and Opportunities

ANDA Litigation

Source: https://www.greyb.com/blog/drug-patents-expiring-2024/


The pharmaceutical industry is undergoing a important phase as numerous patents for key drugs are slated to expire in 2024. This impending expiration of patents signals a significant shift in the market landscape, opening doors for generic versions of these medications. Understanding the dynamics of these expirations is crucial for stakeholders, including pharmaceutical companies, healthcare providers, and consumers.

Overview of Patents Expiring in 2024

The following drugs are among those with patents expiring in 2024:

  • Mulpleta (Lusutrombopag) - Used in treating Thrombocytopenia.
  • Invokamet XR (Canagliflozin; Metformin Hydrochloride) - Indicated for Type 2 Diabetes Mellitus.
  • Revlimid (Lenalidomide) - An essential medication for Multiple Myeloma and Myelodysplastic Syndromes.
  • Rydapt (Midostaurin) - Prescribed for Acute Myeloid Leukemia.
  • Prevymis (Letermovir) - Treating Cytomegalovirus (CMV) infection.
  • Vyndaqel (Tafamidis Meglumine) - For Transthyretin Amyloid Polyneuropathy.
  • Lynparza (Olaparib) - Used against Advanced Ovarian Cancer, Fallopian Tube Cancer.
  • Tasigna (Nilotinib) - A medication for Chronic Myelogenous Leukemia.
  • Xopenex HFA (Levalbuterol Tartrate) - Effective in Asthma and COPD.
  • Vandazole (Metronidazole) - For Bacterial Vaginosis.

Market Implications

The expiration of these patents will impact market dynamics significantly. The availability of generic versions may lead to a more competitive landscape, potentially driving down prices and increasing accessibility for patients. Generic drug manufacturers will likely capitalize on this opportunity, introducing more affordable alternatives to branded medications.

Opportunities and Challenges

While patent expiration presents lucrative opportunities for generic drug companies, it also poses challenges. Legal and technological hurdles often hinder the smooth entry of generic versions into the market. Generic drug manufacturers must conduct thorough research, address legal implications, and overcome technological barriers to ensure a successful market entry.